Market Reports

A modern take on sterility assurance

Pharmaceutical manufacturers are increasingly looking for strategies to address containment risks. Christian Dunne of ChargePoint Technology sheds light on the benefit of split butterfly valve technology (SBV) in the aseptic processing of sterile active APIs and the final product

A look back at 2017 healthcare transactions

Last year, 2017, saw 2011 deals complete, with Q2 showing the strongest performance with 29.4%, followed by Q1 with 27.6%, Q3 with 24.1% and Q4 with 18.9%

Weathering the Brexit storm

The effective use of technology could facilitate regulatory compliance for pharmaceutical companies

Performance validation: HPAPI containment testing in a risk-based era

Taking a more automated approach to validation testing paves the way to capturing more repeatable and reliable data, thereby improving levels of containment performance

Gene transfer therapy approved for the treatment of ALL: part I

In August 2017, Novartis received FDA approval for its chimeric antigen receptor T (CAR-T) cell therapy, Kymriah, for the treatment of children and young adults with B-cell acute lymphoblastic leukaemia (ALL)

The race to be first: drug delivery systems for biosimilars

For biosimilar manufacturers, the market potential is significant, especially for those that are first to market

Improving cold chain performance and reliability

The need to mitigate risks within global pharmaceutical supply chain logistics is driving innovation within the temperature-controlled packaging sector

Trending Articles

  1. NICE recommends enfortumab vedotin with KEYTRUDA for adults in England/Wales with untreated metastatic urothelial cancer The results from the Phase III study EV-302/KN-A39 showed nearly a doubling of survival rates in patients compared with those who received platinum-based chemotherapy, which is the current standard of care in the UK
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    How CRDMOs are shaping the next generation of antibody-drug conjugates To explore how CRDMOs are leading innovation in ADC development, Dr Kevin Robinson spoke with Srivats Rajagopal, Senior Director, Cell and Protein Sciences, Biology Solutions at Aragen Life Sciences, about key technological advancements and evolving partnership models that are redefining what it means to outsource in this space
  3. Influence of material and capsule filling process on DPI aerosolisation performance The effect of capsule filling parameters on emitted dose and fine particle fraction by a DPI was investigated using a benchtop capsule filling device. Compression was the parameter that affected weight and emitted fraction the most, whereas the type of coarse lactose seems to influence the fine particle fraction
  4. The economic advantages of continuous flow chemistry Batch production has been the traditional workhorse of the pharmaceutical manufacturing sector. However, economic advantages are taking continuous flow out of the realm of a niche technology for high energy, hazardous reactions to become an essential part of the small molecule manufacturing toolkit
  5. Recombinant versus synthetic peptide synthesis: the perks and drawbacks Since the introduction of novel peptide drugs into the market, the demand for polypeptide manufacturing has significantly increased, reports Dr Philipp Markolin

Upcoming event

POWTECH

23-25 September 2025 | Exhibition | Nuremberg, Germany See all